Properties of azithromycin that enhance the potential for compliance in children with upper respiratory tract infections

Pediatric Infectious Disease Journal

Volumn 15, Issue 9 SUPPL., 1996, Pages

  Powers, Jerold L ^a,b  

^a Hill Top Research Inc   (United States)

^b NONE   (United States)

Author keywords

Azithromycin; compliance; efficacy; pharmacokinetics; spectrum of activity; taste

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFPODOXIME PROXETIL; CEFPROZIL; CLARITHROMYCIN; LORACARBEF;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; PATIENT COMPLIANCE; PHARYNGITIS; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHILD; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PATIENT COMPLIANCE; RESPIRATORY TRACT INFECTIONS; SUSPENSIONS; TASTE;

EID: 0029813293     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199609000-00001     Document Type: Article

References (48)

1. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26:1253-61.
2. Retsema J, Girard A, Schelkly W, et al. Spectrum and mode of action of azithromycin (CP-62 993), a new 15-membered-ring macrolide with improved potency against Gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.
3. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988;32:1710-9.
4. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991;91(Suppl 3A):5S-11S.
5. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissue. J Antimicrob Chemother 1990;25(Suppl A):73-82.
6. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992;23:106-31.
7. Hopkins SJ. Clinical toleration and safety of azithromycin in adults and children. Rev Contemp Pharmacother 1994;5: 383-9.
8. Steigbigel NH. Macrolides and clindamycin. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone, 1995:334-46.
9. Anderson R, Joone G, van Rensburg CEJ. An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrob Chemother 1988;22:923-33.
10. Ishiguro M, Koga H, Kohno S, Hayashi T, Yamaguchi K, Hirota M. Penetration of macrolides into human polymorphonuclear leucocytes. J Antimicrob Chemother 1989;24:719-29.
11. Jorgensen JH, Maher LA, Howell AW. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae. Antimicrob Agents Chemother 1991;35: 1524-6.
12. Hardy DJ, Swanson RN, Rode RA, Marsh K, Shipkowitz NL, Clement JJ. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrob Agents Chemother 1990;34:1407-13.
13. Bahal N, Nahata MC. The macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992;25:46-55.
14. O'Neill SJ, Millar ED, Coles SJ, Bachand RT. Safety and efficacy of clarithromycin in the treatment of acute mild to moderate respiratory tract infections. Ir Med J 1991;84:33-5.
15. Cockburn J, Gibberd RW, Reid AL, Sanson-Fisher RW. Determinants of non-compliance with short term antibiotic regimens. Br Med J 1987;295:814-8.
16. Grob PR. Antibiotic prescribing practices and patient compliance in the community. Scand J Infect Dis 1992;83:7-14.
17. Dagan R, Shvartzman P, Liss Z. Variation in acceptance of common oral antibiotic suspensions. Pediatr Infect Dis J 1994;13:686-90.
18. Pass RJ. Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. Antimicrob Agents Chemother 1993;37: 2080-6.
19. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U. S. medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
20. McLinn S, Williams D. High incidence of Streptococcus pneumoniae and Haemophilus influenzae (beta-lactamase) resistance in otitis media clinical trial isolates. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995.
21. Physicians' desk reference. 49th ed. Montvale, NJ: Medical Economics Data Production Co, 1995. Package insert for azithromycin.
22. Shepard RM, Falkner FC. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 1990;25(Suppl A):49-60.
23. Dette GA. Vergleich der Gewebegängigkeit von Erythromycin. Infection 1979;7:129-45.
24. Nahata MC, Koranyi KI, Gadgil SD, Hilligoss DM, Fouda HG, Gardner MJ. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993;37:314-6.
25. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993;25:370-4.
26. Retsema JA, Girard AE, Girard D, Milisen WB. Relationship of high tissue concentrations of azithromycin to bactericidal activity and efficacy m vivo. J Antimicrob Chemother 1990; 25(Suppl A):83-9.
27. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62 993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:277-82.
28. Wildfeuer A, Laufen H, Zimmermann T. Distribution of orally administered azithromycin in various blood compartments. Int J Clin Pharmacol Ther 1994;32:356-60.
29. Pukander J. Penetration of azithromycin into middle ear effusion in acute and secretory otitis media in children. Presented at the Second International Conference on Macrolides and Streptogramins, Venice, Italy, January 17 to 22, 1994.
30. Still JG. Management of pediatric patients with group A beta-hemolytic Streptococcus pharyngitis: treatment options. Pediatr Infect Dis J 1995;14(Suppl):S57-61.
31. McLinn S. Double blind and open label studies of azithromycin in the management of acute otitis media in children: a review. Pediatr Infect Dis J 1995;14(Suppl):S61-7.
32. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11:137-62.
33. Moellering RC Jr. Introduction: revolutionary changes in the macrolides and azalide antibiotics. Am J Med 1991;91(Suppl 3A):1S-4S.
34. Bluestone CD. Current therapy for otitis media and criteria for evaluation of new antimicrobial agents. Clin Infect Dis 1992;14(Suppl 2):S197-203.
35. Teele DW, Klein JO, Rosner B, the Greater Boston Otitis Media Study Group. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis 1989;160:83-94.
36. McCracken GH Jr. Emergence of resistant Streptococcus pneumoniae: a problem in pediatrics. Pediatr Infect Dis J 1995;14:424-80.
37. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis media pathogens. Pediatr Infect Dis J 1992;11:S7-11.
38. Aronovitz G. A multicenter, open label trial of azithromycin vs. amoxicillin/clavulanate for the management of acute otitis media in children. Pediatr Infect Dis J 1996;15:S15-9.
39. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984;6:592-9.
40. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-4.
41. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med 1963;268:1334-8.
42. Charney E, Bynum R, Eldredge D, et al. How well do patients take oral penicillin? A collaborative study in private practice. Pediatrics 1967;40:188-95.
43. Nightingale CH, Belliveau PP, Quintiliani R. Cost issues and considerations when choosing antimicrobial agents. Infect Dis Clin Pract 1994;3:8-11.
44. Khurana CM. Issues concerning antibiotic use in child care settings. Pediatr Infect Dis J 1995;14(Suppl):S34-8.
45. Lisby-Sutch SM, Nemec-Dwyer MA, Decter RG, Gaur SM. Therapy of otitis media. Clin Pharm 1990;9:15-34.
46. Demers DM, Chan DS, Bass JW. Antimicrobial drug suspensions: a blinded comparison of taste of twelve common pediatric drugs including cefixime, cefpodoximo, cefprozil and loracarbef. Pediatr Infect Dis J 1994;13:87-9.
47. Bergeron MG, Ahronheim G, Richard JE, et al. Comparative efficacies of erythromycin-sulfisoxazole and cefaclor in acute otitis media: a double blind randomized trial. Pediatr Infect Dis J 1987;6:654-60.
48. Odio CM, Kusmiesz H, Shelton S, Nelson JD. Comparative treatment trial of Augmentin versus cefaclor for acute otitis media with effusion. Pediatrics 1985;75:819-26.